Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares Issued Shares Outstanding Shares Outstanding

Ratios

Contineum Therapeutics (CTNM) Preferred Shares Issued (2023)

Contineum Therapeutics has reported Preferred Shares Issued over the past 1 years, most recently at $10.2 million for Q3 2023.

Quarterly results put Preferred Shares Issued at $10.2 million for Q3 2023, changed N/A from a year ago — trailing twelve months through Dec 2024 was $10.2 million (changed N/A YoY), and the annual figure for FY2023 was $60.1 million, changed.
Preferred Shares Issued for Q3 2023 was $10.2 million at Contineum Therapeutics, down from $27.9 million in the prior quarter.
Over the last five years, Preferred Shares Issued for CTNM hit a ceiling of $27.9 million in Q2 2023 and a floor of $10.2 million in Q3 2023.